Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $65 and keeps a Buy rating on the shares. Q1 marked the transition of the company’s out-licensing centric business model to launching wholly-owned medicines and given the “dood early launch for Tryngolza,” and breadth of the initial demand, the firm’s view remains above consensus for FY25, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Q1 Performance and Future Growth Potential Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q1 2025 Results
- Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges
- Ionis Pharmaceuticals: Strong Financial Performance and Strategic Partnerships Justify Buy Rating Despite Adjusted Price Target
- Ionis Pharmaceuticals: Strong Performance and Promising Pipeline Justify Buy Rating